A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Adequately Responded by Fimasartan 30 mg

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05878561

Enrollment

248

Registered

2023-05-26

Start date

2022-11-09

Completion date

2024-12-02

Last updated

2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Brief summary

The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg

Interventions

DRUGFimasartan + Indapamide

a fixed dose combination

DRUGFimasartan + Indapamide placebo

a fixed dose combination

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Inclusion Criteria: * Patients with uncontrolled essential hypertension at screening(V1) under the following criteria: * Naïve : 140 mmHg ≤ SiSBP \< 180 mmHg * Use antihypertensive drugs : 130 mmHg ≤ SiSBP \< 180 mmHg * Patients with uncontrolled essential hypertension at randomization(V2) after Fimasartan 30mg monotherapy for 4 weeks under the following criteria: * Selected reference arm : 140 mmHg ≤ SiSBP \< 180 mmHg (For patients with cardiovascular disease, diabetes or chronic kidney disease (CKD) with albuminuria, 130 mmHg ≤ SiSBP \< 180 mmHg) * Treatment compliance of Fimasartan 30 mg ≥70% at baseline visit (V2) * Voluntarily provided a written consent to participate in this clinical study * Able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion *

Exclusion criteria

* Patients taking three or more antihypertensive drugs of different families * Patients with blood pressure results showing SiSBP ≥ 180 mmHg or SiDBP ≥ 110 mmHg in the selected reference arm at screening(V1) and randomization(V2) * Patients with a difference of SiSBP ≥ 20 mmHg and SiDBP ≥ 10 mmHg in blood pressure measured three times on both arms at screening(V1) * Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, Primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.) * Patients with orthostatic hypotension accompanied by symptoms * Patients who need to be administered in combination with antihypertensive drugs other than investigational product while participating in clinical trials

Design outcomes

Primary

Measure	Time frame	Description
Sitting systolic blood pressure	8weeks from Baseline Visit	The change of sitting systolic blood pressure

Secondary

Measure	Time frame	Description
Sitting systolic blood pressure	4weeks from Baseline Visit	The change of sitting systolic blood pressure

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026